Nine years after selling Medivation to Pfizer for $14 billion, David Hung, M.D., is going toe to toe with the New York ...

Nuvation Bio (NUVB) wins U.S. FDA approval for its oral antitumor agent Ibtrozi as a treatment for certain patients with ...

"The FDA approval of IBTROZI marks a major milestone in the evolution of targeted therapy for advanced ROS1-positive NSCLC," said David Hung, M.D., Founder, President and Chief Executive Officer of ...

Study reveals the advantages and pitfalls of adding a TKI to a monoclonal antibody after chemoradiation for non-small cell ...

Biomarker-targeted adjuvant therapy improved survival in early-stage NSCLC, highlighting the importance of testing and ...

Black Diamond Therapeutics's novel EGFR inhibitor shows promise in addressing resistance mutations in NSCLC and glioblastoma.

The annual meeting of the American Society of Clinical Oncology was held from May 31 to June 3 in Chicago and hosted more ...

Using a 14-gene test to guide chemotherapy significantly improved disease-free survival in patients with early nonsquamous ...

In May, the FDA granted significant drug approvals across various therapeutic areas, marking notable progress in expanding treatment options for patients.

Toxicities related to Teliso-V are manageable for patients with c-Met overexpressing non-small cell lung cancer, according to ...

A recent study reveals promising outcomes for lung cancer patients who undergo rechallenge with different RET inhibitors ...

Non-small cell lung cancer (NSCLC) accounts for the majority of lung cancer cases and remains a leading cause of cancer ...